Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq

Expert Review of Molecular Diagnostics

Volumn 15, Issue 6, 2015, Pages 715-719

  Bratman, Scott V ^a   Newman, Aaron M ^b   Alizadeh, Ash A ^b   Diehn, Maximilian ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GENETICS; CANCER PERSONALIZED PROFILING DEEP SEQUENCING; CANCER PROGNOSIS; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; COPY NUMBER VARIATION; DIAGNOSTIC IMAGING; DNA DETERMINATION; EDITORIAL; GENE REARRANGEMENT; GENOTYPE; HEALTH CARE UTILIZATION; HUMAN; INDEL MUTATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; POINT MUTATION; POSITRON EMISSION TOMOGRAPHY; TREATMENT RESPONSE; TUMOR VOLUME; BLOOD; DRUG RESISTANCE; EARLY CANCER DIAGNOSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; MORTALITY; MUTATION; NEOPLASMS; PERSONALIZED MEDICINE; PROCEDURES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STANDARDS;

BIOMARKERS, TUMOR; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; EARLY DETECTION OF CANCER; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASMS; PRECISION MEDICINE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN;

EID: 84929860892     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.1019476     Document Type: Editorial

References (30)

1. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 2014;6(224):224-224
2. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368(13):1199-209
3. Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. ASCO Meeting Abstracts 2014;32(15 suppl):8504
4. Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a Phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 2012;18(8):2391-401
5. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20(5):548-54
6. Taniguchi K, Uchida J, Nishino K, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011;17(24):7808-15
7. Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20(6):1698-705
8. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32(6):579-86
9. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14(9):985-90
10. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA 1999;96(16): 9236-41
11. Narayan A, Carriero NJ, Gettinger SN, et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res 2012;72(14):3492-8
12. Hindson CM, Chevillet JR, Briggs HA, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 2013;10(10):1003-5
13. Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012;4(162):162ra154
14. Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497(7447):108-12
15. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4(136):136ra168
16. Kinde I, Wu J, Papadopoulos N, et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA 2011; 108(23):9530-5
17. Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA 2010;303(16): 1625-31
18. Huang K, Dahele M, Senan S, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)-can we distinguish recurrence from fibrosis A systematic review of the literature. Radiother Oncol 2012;102(3):335-42
19. Ferrari A, Miceli R, Meazza C, et al. Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J Clin Oncol 2010;28(8):1322-8
20. Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 2010;28(24):3838-43
21. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the cancer and leukemia Group B, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol 2008;26(31): 5043-51
22. Wu X, Zhang J, He X, et al. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J Gastrointest Surg 2012;16(3):646-55
23. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344(14):1038-42
24. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19(10):2587-95
25. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365(5):395-409
26. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-8
27. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367(7):595-605
28. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012;307(22):2418-29
29. Biesecker LG, Spinner NB. A genomic view of mosaicism and human disease. Nat Rev Genet 2013;14(5):307-20
30. Castells A, Puig P, Mora J, et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 1999;17(2): 578-84